At the news
? NEUTRALIMPACT 4/10 PRESS-RELEASE filed Mar 2, 2026 at 07:00 ET
Sionna Therapeutics reported financial results for Q4 and full year 2025, highlighting increased R&D and G&A spending, a growing net loss, and a strong cash position of $310.3 million that funds operations into 2028. The company advanced its NBD1 stabilizer pipeline with Phase 1/2a trials on track for mid-2026 readouts, but no revenue-generating products or positive clinical outcomes were reported.
- No revenue generated; biopharma company in clinical stage with no commercial products
- Net loss increased to $75.3 million in 2025 from $61.7 million in 2024
- Cash and equivalents totaled $310.3 million as of December 31, 2025, up from $168.0 million in 2024
- SION-719 and SION-451 Phase 1 trials completed with topline data expected mid-2026
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access